{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:42:43Z","timestamp":1790664163111,"version":"4.1.0"},"reference-count":29,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci Atheroscler Dis"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Paroxysmal atrial fibrillation (PAF) is a\u00a0well-documented prothrombotic state that carries significant embolic risk. However, precise hemostatic changes in the very early stage of the disease are not completely studied. The aim of the study was to study von Willebrand factor (vWF) and coagulation factor VIII (FVIII) plasma levels and activity in the first hours (up to 24 h) of PAF clinical manifestation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>We selected consecutively 51 non-anticoagulated patients (26 men, 25 women, mean age: 59.84 \u00b11.60) with PAF and 52 controls (26 men, 26 women, mean age: 59.50 \u00b11.46 years) corresponding in gender, accompanying diseases and conducted treatment. The indicators were examined using enzyme-linked immunoassays and photometric tests.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients were hospitalized between the 2nd and 24th h after the onset of arrhythmia (mean: 8.14 \u00b10.74 h). Higher FVIII levels (107.52 \u00b13.48% vs. 93.85 \u00b12.93%, p &lt; 0.05) and activity (200.03 \u00b111.11% vs. 109.73 \u00b14.90%, p &lt; 0.001) were found in the PAF group. vWF levels (178.40 \u00b112.95% vs. 119.53 \u00b16.12%, p &lt; 0.001) and activity (200.92 \u00b112.45% vs. 110.80 \u00b15.14%, p &lt; 0.001) were also higher. These changes did not depend on age, sex, body mass index or CHA2DS2-VASc score in the PAF group (p &gt; 0.05). PAF duration was a\u00a0significant predictor of increased FVIII levels and activity. Increased PAF duration was followed by increased values of the factors (r = 0.85, p &lt; 0.001; r = 0.83, p &lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results presented an activated coagulation cascade and endothelial injury, suggesting hypercoagulability still in the early hours of PAF. These changes in PAF did not correlate with CHA2DS2-VASc score risk factors, outlining PAF as a\u00a0possible independent embolic risk factor.<\/jats:p><\/jats:sec>","DOI":"10.5114\/amsad.2020.97101","type":"journal-article","created":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T21:06:40Z","timestamp":1595797600000},"page":"140-147","source":"Crossref","is-referenced-by-count":8,"title":["Paroxysmal atrial fibrillation: changes in factor VIII and von Willebrand factor impose early hypercoagulability"],"prefix":"10.5114","volume":"5","author":[{"given":"Mariya","family":"Negreva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krasimira","family":"Prodanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Vitlianova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Madjova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"ref-619347","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-319-76723-9_1","volume-title":"Congenital Bleeding Disorders","author":"Dorgalaleh A","year":"2018","unstructured":"Dorgalaleh A, Daneshi M, Rashidpanah J, Roshani Yasaghi E, Dorgalaleh A. (2018). Congenital Bleeding Disorders. 3-26. Springer International Publishing, Cham."},{"key":"ref-619348","first-page":"785","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova M","year":"2017","unstructured":"Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. (2017). Thrombosis and platelets: an update Eur Heart J. 38: 785-91.","journal-title":"Eur Heart J"},{"key":"ref-619349","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.thromres.2014.08.014","article-title":"Thrombosis: a major contributor to global disease burden","volume":"134","author":"ISTH Steering","year":"2014","unstructured":"ISTH Steering Committee for World Thrombosis Day. (2014). Thrombosis: a major contributor to global disease burden Thromb Res. 134: 931-8.","journal-title":"Thromb Res"},{"key":"ref-619350","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano R","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet. 380: 2095-128.","journal-title":"Lancet"},{"key":"ref-619351","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCEP.112.970749","article-title":"Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry","volume":"5","author":"Chiang CE","year":"2012","unstructured":"Chiang CE, Naditch-Br\u00fbl\u00e9 L, Murin J, et al. (2012). Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry Circ Arrhythm Electrophysiol. 5: 632-9.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref-619352","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annemergmed.2004.02.016","article-title":"Electrical cardioversion of emergency department patients with atrial fibrillation","volume":"44","author":"Burton JH","year":"2004","unstructured":"Burton JH, Vinson DR, Drummond K, Strout TD, Thode HC, McInturff JJ. (2004). Electrical cardioversion of emergency department patients with atrial fibrillation Ann Emerg Med. 44: 20-30.","journal-title":"Ann Emerg Med"},{"key":"ref-619353","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijcard.2014.01.099","article-title":"Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study","volume":"172","author":"Crijns HJGM","year":"2014","unstructured":"Crijns HJGM, Weijs B, Fairley AM, et al. (2014). Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study Int J Cardiol. 172: 588-94.","journal-title":"Int J Cardiol"},{"key":"ref-619354","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0196-0644(99)70300-8","article-title":"Cardioversion of paroxysmal atrial fibrillation in the emergency department","volume":"33","author":"Michael JA","year":"1999","unstructured":"Michael JA, Stiell IG, Agarwal S, Mandavia DP. (1999). Cardioversion of paroxysmal atrial fibrillation in the emergency department Ann Emerg Med. 33: 379-87.","journal-title":"Ann Emerg Med"},{"key":"ref-619355","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jacc.2013.04.089","article-title":"Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study","volume":"62","author":"Airaksinen KEJ","year":"2013","unstructured":"Airaksinen KEJ, Gr\u00f6nberg T, Nuotio I, et al. (2013). Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study J Am Coll Cardiol. 62: 1187-92.","journal-title":"J Am Coll Cardiol"},{"key":"ref-619356","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/jama.2014.3824","article-title":"Time to cardioversion for acute atrial fibrillation and thromboembolic complications","volume":"312","author":"Nuotio I","year":"2014","unstructured":"Nuotio I, Hartikainen JEK, Gr\u00f6nberg T, Biancari F, Airaksinen KE. (2014). Time to cardioversion for acute atrial fibrillation and thromboembolic complications JAMA. 312: 647-9.","journal-title":"JAMA"},{"key":"ref-619357","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2516.2010.02303.x","article-title":"Haemophilia A and von Willebrand\u2019s disease","volume":"16","author":"Goodeve AC","year":"2010","unstructured":"Goodeve AC, Ros\u00e9n S, Verbruggen B. (2010). Haemophilia A and von Willebrand\u2019s disease Haemophilia. 16: 79-84.","journal-title":"Haemophilia"},{"key":"ref-619358","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood-2014-08-528398","article-title":"Diagnostic approach to von Willebrand disease","volume":"125","author":"Christopher N","year":"2015","unstructured":"Christopher N, Motto DG, Di Paola J. (2015). Diagnostic approach to von Willebrand disease Blood. 125: 2029-37.","journal-title":"Blood"},{"key":"ref-619359","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2007-12-130740","article-title":"Basal secretion of von Willebrand factor from human endothelial cells","volume":"112","author":"Giblin JP","year":"2008","unstructured":"Giblin JP, Hewlett LJ, Hannah MJ. (2008). Basal secretion of von Willebrand factor from human endothelial cells Blood. 112: 957-64.","journal-title":"Blood"},{"key":"ref-619360","unstructured":"NOT SUPPORTED YET"},{"key":"ref-619361","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","author":"Kirchhof P","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, et al, ESC Scientific Document Group. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS Eur J Cardiothorac Surg. 50: e1-88.","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref-619362","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/1076029615571630","article-title":"Factoring in factor VIII with acute ischemic stroke","volume":"21","author":"Siegler JE","year":"2015","unstructured":"Siegler JE, Samai A, Albright K, Boehme AK, Martin-Schild S. (2015). Factoring in factor VIII with acute ischemic stroke Clin Appl Thromb Hemost. 21: 597-602.","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref-619363","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle PA","year":"2000","unstructured":"Kyrle PA, Minar E, Hirschl M, et al. (2000). High plasma levels of factor VIII and the risk of recurrent venous thromboembolism N Engl J Med. 343: 457-62.","journal-title":"N Engl J Med"},{"key":"ref-619364","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00415-018-8887-7","article-title":"Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study","volume":"265","author":"Vecht L","year":"2018","unstructured":"Vecht L, Zuurbier SM, Meijers JCM, Coutinho JM. (2018). Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study J Neurol. 265: 1612-7.","journal-title":"J Neurol"},{"key":"ref-619365","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.ejvs.2007.05.019","article-title":"A rare case of thromboembolism in a 21-year old female with elevated factor VIII","volume":"34","author":"Bosma J","year":"2007","unstructured":"Bosma J, Rijbroek A, Rauwerda JA. (2007). A rare case of thromboembolism in a 21-year old female with elevated factor VIII Eur J Endovasc Surg. 34: 592-4.","journal-title":"Eur J Endovasc Surg"},{"key":"ref-619366","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1567202612666150102153447","article-title":"Factor VIII levels are associated with ischemic stroke, stroke subtypes and neurological worsening","volume":"12","author":"Kuo CY","year":"2015","unstructured":"Kuo CY, Lin CH, Kuo YW, et al. (2015). Factor VIII levels are associated with ischemic stroke, stroke subtypes and neurological worsening Curr Neurovasc Res. 12: 85-90.","journal-title":"Curr Neurovasc Res"},{"key":"ref-619367","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2017-02-767079","article-title":"Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex","volume":"130","author":"Kamikubo Y","year":"2017","unstructured":"Kamikubo Y, Mendolicchio GL, Zampolli A, et al. (2017). Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex Blood. 130: 1661-70.","journal-title":"Blood"},{"key":"ref-619368","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(03)00227-8","article-title":"Coagulation factor VIII: structure and stability","volume":"259","author":"Wang W","year":"2003","unstructured":"Wang W, Wang YJ, Kelner DN. (2003). Coagulation factor VIII: structure and stability Int J Pharm. 259: 1-15.","journal-title":"Int J Pharm"},{"key":"ref-619369","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3678017","article-title":"Intracardiac hemostasis and fibrinolysis parameters in patients with atrial fibrillation","volume":"2017","author":"T\u00f3th NK","year":"2017","unstructured":"T\u00f3th NK, Csan\u00e1di Z, Hajas O, et al. (2017). Intracardiac hemostasis and fibrinolysis parameters in patients with atrial fibrillation BioMed Res Int. 2017: 1-10.","journal-title":"BioMed Res Int"},{"key":"ref-619370","doi-asserted-by":"crossref","first-page":"e0124716","DOI":"10.1371\/journal.pone.0124716","article-title":"Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression","volume":"10","author":"Wu N","year":"2015","unstructured":"Wu N, Tong S, Xiang Y, et al. (2015). Association of hemostatic markers with atrial fibrillation: a meta-analysis and meta-regression PLoS One. 10: e0124716.","journal-title":"PLoS One"},{"key":"ref-619371","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.ijcard.2007.06.143","article-title":"Inadvertend catch of a factor VIII rich thrombus with a femoral sheath during cardiac catheterization","volume":"130","author":"Hammw\u00f6hner M","year":"2008","unstructured":"Hammw\u00f6hner M, Tautenhahn J, Kuester D, Goette A. (2008). Inadvertend catch of a factor VIII rich thrombus with a femoral sheath during cardiac catheterization Int J Cardiol. 130: e39-41.","journal-title":"Int J Cardiol"},{"key":"ref-619372","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1055\/s-0038-1656061","article-title":"High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction","volume":"77","author":"O\u2019Donnell J","year":"1997","unstructured":"O\u2019Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M. (1997). High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction Thromb Haemost. 77: 825-8.","journal-title":"Thromb Haemost"},{"key":"ref-619373","first-page":"s3","article-title":"Role of von Willebrand factor in the haemostasis","volume":"9","author":"Peyvandi F","year":"2011","unstructured":"Peyvandi F, Garagiola I, Baronciani L. (2011). Role of von Willebrand factor in the haemostasis Blood Transfus. 9: s3-8.","journal-title":"Blood Transfus"},{"key":"ref-619374","first-page":"17","article-title":"Von Willebrand factor: form for function","volume":"40","author":"Yee A","year":"2014","unstructured":"Yee A, Kretz CA. (2014). Von Willebrand factor: form for function Semin Thromb Haemost. 40: 17-27.","journal-title":"Semin Thromb Haemost"},{"key":"ref-619375","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/hrt.2007.135277","article-title":"Endothelial dysfunction and pathophysiological correlates in atrial fibrillation","volume":"95","author":"Guazzi M","year":"2009","unstructured":"Guazzi M, Arena R. (2009). Endothelial dysfunction and pathophysiological correlates in atrial fibrillation Heart. 95: 102-6.","journal-title":"Heart"}],"container-title":["Archives of Medical Science \u2013 Atherosclerotic Diseases"],"original-title":[],"link":[{"URL":"https:\/\/amsad.termedia.pl\/pdf-122774-71870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/amsad.termedia.pl\/pdf-122774-71870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:38:20Z","timestamp":1653554300000},"score":1,"resource":{"primary":{"URL":"https:\/\/amsad.termedia.pl\/Paroxysmal-atrial-fibrillation-changes-in-factor-VIII-and-von-Willebrand-factor-impose,122774,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["122774"],"URL":"https:\/\/doi.org\/10.5114\/amsad.2020.97101","relation":{},"ISSN":["2451-0629"],"issn-type":[{"value":"2451-0629","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,11]]}}}